-
Min Investment
-
$497
-
Expected Close Date
-
June 24, 2024
-
Target Raise
-
$15.00K-$1.24M
-
Security Price
-
$3.50
- Number of Employees
- 1
- Cash
- $164
- Revenue
- $0
- Short Term Debt
- $21,704
- Cost of Goods
- $0
- Long Term Debt
- $0
- Net Income
- $-179,813
Company Description
Emet Surgical is aiming to improve cancer surgery outcomes by offering innovative tools for tumor marking, enabling better collaboration between surgeons and pathologists. Our goal is to enhance patient results while providing improved ROI for healthcare providers and insurers. Emet Surgical is a pre-revenue business currently in the development stage.
Key Deal Facts
We believe our TrueMargin™ tools can help revolutionize cancer surgeries, reducing re-operation rates with innovative Colored Marking Sutures and Clips.
With millions worldwide undergoing breast cancer surgeries yearly, Emet Surgical's technology addresses a pressing need for improved surgical outcomes, offering substantial market potential.*
Backed by patent claims filed for TrueMargin and TrueGastro and expanding our portfolio with applications for packaging and manufacturing processes, our goal is FDA clearance in Q2 2024.
Emet Surgical is a pre-revenue business currently in the development stage.